Oracle Recognized as a Leader in 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services
Werte in diesem Artikel
AUSTIN, Texas, Sept. 30, 2025 /PRNewswire/ -- Oracle has been recognized as a leader in the 2025 IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services 2025 Vendor Assessment1. The report notes that, "Oracle is bringing together its Safety One Platform, Oracle Real-World Data (ORWD), Health Data Intelligence (HDI) platform, and Oracle Cloud Infrastructure (OCI) Artificial Intelligence (AI) Services to drive its precision PV strategy."
"By bringing together its solutions for safety, data, and intelligence, Oracle is building a connected ecosystem for precision PV," said Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology, IDC. "This approach, combined with their regulatory expertise and extensive customer base, positions Oracle to guide the industry towards more proactive and intelligent drug safety management."
"This recognition from the IDC MarketScape further validates Oracle's pivotal role in advancing drug safety innovation and the significant investments we have made in R&D to help our customers more swiftly and safely get life-saving treatments to market," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We further believe Oracle's Safety One platform, combined with our deep domain and AI expertise, is equipping organizations to confidently navigate the complexities of modern pharmacovigilance, helping to ensure they are future-ready for evolving regulatory landscapes and safety challenges."
The report noted, "Oracle has been providing PV technology solutions and consulting services for close to three decades. It estimates that its PV revenue will grow by 20% annually in the next three years and reports that it owns close to 60% of the PV software market share. It has supported over 100,000 clinical trials, 90% of which included a PV focus. It has over 400 direct PV customers and has acquired close to 100 new customers in the past 12 months. Over 70% of all drug Individual Case Safety Reports (ICSRs) and more than 90% of all vaccine ICSRs reported to the FDA since 2017 originate in Argus."
By continuously delivering advanced, AI-powered solutions and comprehensive services, Oracle empowers its customers to optimize pharmacovigilance operations and uphold the highest standards of patient safety.
To access the 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services excerpt visit: https://www.oracle.com/life-sciences/safety-solutions/
About IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements—empowering the life sciences industry to improve patient outcomes. Learn more at www.oracle.com/life-sciences.
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
1 2025 IDC MarketScape for Worldwide Life Science R&D Pharmacovigilance (PV) Technology Solutions and Consulting Services (doc # US53669225, July 2025) - https://www.oracle.com/life-sciences/safety-solutions/
View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-recognized-as-a-leader-in-2025-idc-marketscape-for-worldwide-life-science-rd-pharmacovigilance-technology-solutions-and-consulting-services-302569964.html
SOURCE Oracle
Übrigens: Oracle und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Oracle
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Oracle
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Oracle Corp.
Analysen zu Oracle Corp.
Datum | Rating | Analyst | |
---|---|---|---|
22.09.2025 | Oracle Buy | Jefferies & Company Inc. | |
15.09.2025 | Oracle Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
15.09.2025 | Oracle Buy | Jefferies & Company Inc. | |
11.09.2025 | Oracle Kaufen | DZ BANK | |
10.09.2025 | Oracle Neutral | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
22.09.2025 | Oracle Buy | Jefferies & Company Inc. | |
15.09.2025 | Oracle Buy | Jefferies & Company Inc. | |
11.09.2025 | Oracle Kaufen | DZ BANK | |
10.09.2025 | Oracle Buy | UBS AG | |
10.09.2025 | Oracle Buy | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
15.09.2025 | Oracle Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
10.09.2025 | Oracle Neutral | JP Morgan Chase & Co. | |
10.09.2025 | Oracle Sector Perform | RBC Capital Markets | |
09.09.2025 | Oracle Sector Perform | RBC Capital Markets | |
08.09.2025 | Oracle Neutral | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
13.12.2022 | Oracle Sell | Goldman Sachs Group Inc. | |
21.10.2022 | Oracle Sell | Goldman Sachs Group Inc. | |
19.03.2019 | Oracle Verkaufen | DZ BANK | |
17.09.2015 | Oracle Sell | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
08.01.2015 | Oracle Sell | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Oracle Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen